HTG - Model EdgeSeq - Precision Immuno-Oncology Panel
From Gene Expression Profiling Panels - HTG EdgeSeq RUO Panels
The next-generation sequencing (NGS)-based HTG EdgeSeq Precision Immuno-Oncology Panel is designed to measure the immune response both inside the tumor and the surrounding microenvironment. HTG’s quantitative nuclease protection assay does not require nucleic acid extraction and is automated using the HTG EdgeSeq processor. By leveraging the high sensitivity and dynamic range of NGS instrumentation, this powerful tool interrogates 1,392 genes from a single section of formalin-fixed, paraffin-embedded (FFPE) tissue, extracted RNA, or PAXgene samples.
Features & Benefits
- Small sample input: test specific tumor microenvironment (TME) regions or needle core biopsies
- 1,392 genes focused on tumor/immune interaction: see a broader view of the immune response in solid and liquid tumors
- FFPE and PAXgene samples: immunophenotype lymphocytes from both the tumor and peripheral blood
- Tumor subtyping: categorize tumors based on previously defined molecular expression and immune response phenotypes
- Simplified data analysis: analyze the result without a complicated pipeline
Research Applications
The breadth of the immune response in a tumor can be measured using the HTG EdgeSeq Precision Immuno-Oncology Panel. Relatively higher levels of IFNG (interferon γ), a key pro-inflammation cytokine, are measured in non-small cell lung cancer samples 3 and 5. IFNG production stimulates the production of T-cell attractant chemokines CXCL9, CXCL10, and CCL5, with a subsequent increase in production of cytolytic molecules such as perforin and granzymes.
Immune loads of NSCLC tumors were assessed using T cell (CD3, CD4, and CD8) markers as well as CD68 (macrophages, myeloid cells). A range of expression was obtained indicating variable loads of immune cells.
Genes associated with WNT (WNT5A) and EMT drivers (ZEB1, TWIST1) are more highly expressed in tumors with lower immune loads. NK cells (NCAM1) are seen at higher levels in tumors with WNT and/or EMT activity, consistent with the literature report.
- TCGA tumor-subtyping
- Immunophenotyping TILs
- Immunoresistance pathways
- Tumor Inflammation
- Cytokine Profiling
- Immunosuppression phenotyping
- DNA repair mechanisms
- Drug target assessment
HTG EdgeSeq Reveal for Precision Immuno-Oncology Panel - Advancing Precision Medicine
HTG EdgeSeq Reveal is a powerful software product that streamlines analysis of biomarker data from samples analyzed with the
HTG EdgeSeq Precision Immuno-Oncology Panel on the HTG EdgeSeq system. HTG EdgeSeq Reveal enables characterization and visualization of immune response in the tumor environment which continues to be an important step in developing biomarker strategies to understand the body’s immune response in relation to cancer biology and potential response to mono- and combination therapies. The HTG EdgeSeq Reveal was designed to be a scalable, flexible data analysis product that will expand with new applications to support HTG’s growing translational research product portfolio.
HTG’s new product, when coupled with the HTG EdgeSeq Precision Immuno-Oncology Panel, enables applications such as:
- Immunophenotyping of tumor infiltrating lymphocytes (TILs)
- Monitoring of immunotherapy response biomarkers
- Elucidation of immune-escape mechanisms known to drive disease progression
Together with the HTG EdgeSeq system, customers using the new HTG EdgeSeq Reveal product will have the ability to conduct molecular profiling using a wide variety of sample types, potentially enabling them to accelerate discovery, support translational applications, and determine potential biomarkers for development of companion diagnostics.
For more information and a product demonstration, contact your HTG representative.
Customer reviews
No reviews were found for HTG - Model EdgeSeq - Precision Immuno-Oncology Panel. Be the first to review!